Signal peptide domains such as Vaxil’s products can induce antigen-specific cellular and humoral responses in a large portion of the population by activating adoptive CD4+ and CD8+ T-cells and antibody responses with antigen-specific anti-tumor function. The unique overexpression and localization of the SP domains close to the cell membrane of cancer cells qualify them as excellent distinct tumor cell targets, which are not present on normal cells and in the circulation.
VAXIL – Creating the ideal immunotherapy
Inducing a Broad
Cancer ResistanceLearn More
Immune ResponseLearn More
Cancer Stem CellsLearn More
First Ever SP-Specific
Antibody PlatformLearn More
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is its ImMucin™ lead immunotherapy product.